TAFAMIDIS

Information current as at: 1 July 2026

PBAC meeting date: November 2026

Legend:

Completed N In progress

Not applicable N Yet to commence

Submission Details

Brand name:: Vyndamax®
Form and strength:: Capsule 61 mg
Submission sponsor:: PFIZER AUSTRALIA PTY LTD
Condition/indication: (therapeutic use): Transthyretin amyloid cardiomyopathy (ATTR-CM)
Listing requested:: To request revision of the previously estimated utilisation of tafamidis for the treatment of ATTR-CM, specifically, an increase to the subsidisation caps for the current Risk Sharing Arrangement (RSA). This item was last considered at the March 2026 PBAC meeting.
Funding program:: PBS General Schedule
Request authority level:: Authority Required (Written or Telephone/Online) for initial treatment Authority Required (Telephone/Online) for continuing treatment
PBAC Submission type:: Change to existing listing (–)
Comment:: --
Other PBAC consideration:: TAFAMIDIS

Submission received for:: November 2026 PBAC meeting
2Opportunity for consumer comment:: Open 22/07/2026 and close 16/09/2026 (see PBS Website)
3PBAC meeting:: Has not yet occurred
4PBAC outcome published:: Pending PBAC outcome (see PBAC Outcomes)
5Lodgement of required documentation:
6Agreement to listing arrangements:: Has not yet commenced
7Government processes:: Has not yet commenced
8Medicine listed on the PBS:: Has not yet occurred

PBAC Recommendation:

Please see the Outcomes from the relevant meeting for more information

Case ID

a1310

Page last updated

23 July 2026

v.9.19